Skip to main content
Erschienen in: Annals of Surgical Oncology 1/2018

03.11.2017 | Melanomas

Wait Times for Melanoma Surgery: Is There an Association with Overall Survival?

verfasst von: Alyson B. Crawford, MD, MSc, Carolyn Nessim, MD, MSc, Joel Weaver, MD, MSc, Carl van Walraven, MD, MSc

Erschienen in: Annals of Surgical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Wait times for access to care have been of increasing interest to public health care officials, health care providers, and the public. There is a paucity of data determining whether extended wait times for melanoma surgery influence patient outcomes. This study measured the association of wait times to surgical treatment with overall survival in patients with melanoma.

Methods

Population-based health administrative databases were used to identify all Ontario adults diagnosed with melanoma between 2004 and 2011, time to various treatment modalities, and death dates. Proportional hazards modeling using time-dependent covariates was used to determine the adjusted association of time from melanoma diagnosis to various post-diagnostic surgical interventions with overall survival.

Results

A total of 2573 patients were included. The 5-year overall survival was 81.1% [95% confidence interval (CI) 79.1–83.0]. Of all patients, 82.9% underwent a wide local excision (WLE) with a median wait time of 43 days [interquartile range (IQR) 24–64], 29.1% underwent a sentinel lymph node biopsy (SNB) with a median wait time of 59 days (IQR 41–81), and 35.0% underwent a lymph node dissection (LND) with a median wait time of 63 days (IQR 43–91). After adjusting for age, sex, rural residence, and risk of mortality from comorbidities, wait times to WLE [hazard ratio (HR) 0.97; 95% CI 0.87–1.08; p = 0.62], SNB [HR 1.04; 95% CI 0.68–1.59; p = 0.86], and LND [HR 0.99; 95% CI 0.89–1.11; p = 0.92] were not associated with overall survival.

Conclusions

Overall survival for patients with melanoma was not influenced by wait times to WLE, SNB, and LND.
Literatur
1.
Zurück zum Zitat Melanoma - SEER Cancer Statistics Review 1975–2013. National Cancer Institute. Accessed 14 Aug 2016. Melanoma - SEER Cancer Statistics Review 1975–2013. National Cancer Institute. Accessed 14 Aug 2016.
2.
Zurück zum Zitat Statistics Canada. Table 103-0553 - New cases and 1991 age-standardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories, annual, CANSIM (database). Accessed 14 Aug 2016. Statistics Canada. Table 103-0553 - New cases and 1991 age-standardized rate for primary cancer (based on the August 2015 CCR tabulation file), by cancer type and sex, Canada, provinces and territories, annual, CANSIM (database). Accessed 14 Aug 2016.
4.
Zurück zum Zitat Murchie P. Treatment delay in cutaneous malignant melanoma: from first contact to definitive treatment. Qual Primary Care. 2007;15:345–51. Murchie P. Treatment delay in cutaneous malignant melanoma: from first contact to definitive treatment. Qual Primary Care. 2007;15:345–51.
5.
Zurück zum Zitat McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol. 2002;147:48–54.CrossRefPubMed McKenna DB, Lee RJ, Prescott RJ, Doherty VR. The time from diagnostic excision biopsy to wide local excision for primary cutaneous malignant melanoma may not affect patient survival. Br J Dermatol. 2002;147:48–54.CrossRefPubMed
6.
Zurück zum Zitat Nelson DW, Stern S, Elashoff DE, Elashoff R, Thompson JF, Mozzillo N, et al. Impact of time between diagnosis and SLNB on outcomes in cutaneous melanoma. J Am Coll Surg. 2017;225:302–11.CrossRefPubMed Nelson DW, Stern S, Elashoff DE, Elashoff R, Thompson JF, Mozzillo N, et al. Impact of time between diagnosis and SLNB on outcomes in cutaneous melanoma. J Am Coll Surg. 2017;225:302–11.CrossRefPubMed
7.
Zurück zum Zitat Stoline MR. The status of multiple comparisons: simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. Am Stat. 1981 35: 134–1. Stoline MR. The status of multiple comparisons: simultaneous estimation of all pairwise comparisons in one-way ANOVA designs. Am Stat. 1981 35: 134–1.
8.
Zurück zum Zitat Austin PC, Walraven CV. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49:940–7.CrossRefPubMedPubMedCentral Austin PC, Walraven CV. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49:940–7.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Austin PC, van Walraven C, Wodchis WP, Newman A, Anderson GM. Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49:932–9CrossRefPubMedPubMedCentral Austin PC, van Walraven C, Wodchis WP, Newman A, Anderson GM. Using the Johns Hopkins Aggregated Diagnosis Groups (ADGs) to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49:932–9CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Morton DL , Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRefPubMedPubMedCentral Morton DL , Thompson JF, Cochran AJ, Mozzillo N, Nieweg OE, Roses DF, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235:879–87.CrossRefPubMedPubMedCentral White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2,505 patients with melanoma with regional lymph node metastasis. Ann Surg. 2002;235:879–87.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat van der Ploeg APT, van Akkooi AC, Rutkowski P, Cook M, Nieweg OE, Rossi CR, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br J Surg. 2012;99:1396–405.CrossRefPubMed van der Ploeg APT, van Akkooi AC, Rutkowski P, Cook M, Nieweg OE, Rossi CR, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. Br J Surg. 2012;99:1396–405.CrossRefPubMed
14.
Zurück zum Zitat Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRefPubMedPubMedCentral Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–7.CrossRefPubMed Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30:1462–7.CrossRefPubMed
16.
Zurück zum Zitat Kretschmer L, Starz H, Thoms KM, Satzger I, Völker B, Jung K, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129:1435–42.CrossRefPubMed Kretschmer L, Starz H, Thoms KM, Satzger I, Völker B, Jung K, et al. Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer. 2011;129:1435–42.CrossRefPubMed
17.
Zurück zum Zitat Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243:693–700.CrossRefPubMedPubMedCentral Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, Beitsch PD, et al. Gender-related differences in outcome for melanoma patients. Ann Surg. 2006;243:693–700.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Mervic L, Leiter U, Meier F, Eigentler T, Forschner A, Metzler G, et al. Sex differences in survival of cutaneous melanoma are age dependent. Melanoma Res. 2011;21:244–52.CrossRefPubMed Mervic L, Leiter U, Meier F, Eigentler T, Forschner A, Metzler G, et al. Sex differences in survival of cutaneous melanoma are age dependent. Melanoma Res. 2011;21:244–52.CrossRefPubMed
19.
Zurück zum Zitat Sedgwick, P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348:g1072.CrossRef Sedgwick, P. Retrospective cohort studies: advantages and disadvantages. BMJ. 2014;348:g1072.CrossRef
Metadaten
Titel
Wait Times for Melanoma Surgery: Is There an Association with Overall Survival?
verfasst von
Alyson B. Crawford, MD, MSc
Carolyn Nessim, MD, MSc
Joel Weaver, MD, MSc
Carl van Walraven, MD, MSc
Publikationsdatum
03.11.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 1/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6146-2

Weitere Artikel der Ausgabe 1/2018

Annals of Surgical Oncology 1/2018 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.